Skip to content

Phase I Clinical Study on the Safety and Efficacy of CD70 CAR-T Cells for Head and Neck Squamous Cell Carcinoma Failing Standard Treatment

Phase I Clinical Study on the Safety and Efficacy of CD70 CAR-T Cells for Head and Neck Squamous Cell Carcinoma Failing Standard Treatment

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000041347
Enrollment
Unknown
Registered
2020-12-23
Start date
2021-03-01
Completion date
Unknown
Last updated
2022-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and neck squamous cell carcinoma

Interventions

Low-dose group:CD70 CAR-T 3×10^7 Intratumor Injection
High-dose group:CD70 CAR-T 3×10^8 Intratumor Injection

Sponsors

The Ninth People's Hospital Affiliated to Medical College of Shanghai Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: All of the following inclusion criteria must be met to be enrolled: 1. Patients with head and neck squamous cell carcinoma who fail to receive standard treatment have no disease progression or other effective treatment options. 2. Patients with head and neck squamous cell carcinoma with CD70 +: CD70 + is defined as tumor tissue immunohistochemical staining >= 2 +, that is, in 10% of tumor cells, the staining intensity is greater than weak to moderate. 3. Systemic assessment of patients with head and neck squamous cell carcinoma was normal within one week before treatment: (1) Hematological examination: neutrophil count (ANC) >= 1.0 x 10^9 / L; hemoglobin >= 9g / dl; platelet count >= 100 x 10^9 / L; Pt or APTT = 60 ml / min. (4) Cardiac function: LVEF >= 52%. 4. The patient or his legal representative agreed to participate in the clinical study and signed the informed consent.

Exclusion criteria

Exclusion criteria: Those who met any of the exclusion criteria were excluded from the study 1. Patients who use glucocorticoid continuously and can't stop taking glucocorticoid; 2. Patients with active autoimmune diseases or immunosuppressed patients (such as immunodeficiency, organ transplantation, etc.); 3. Patients with active infectious diseases, such as hepatitis B, syphilis, etc; 4. Patients with severe systemic diseases such as heart, liver and kidney dysfunction; 5. Patients during pregnancy or lactation; 6. Patients with severe mental illness or poor compliance who cannot complete the treatment.

Design outcomes

Primary

MeasureTime frame
Adverse events;

Secondary

MeasureTime frame
Response evaluation of solid tumor;Quality of Life;

Countries

China

Contacts

Public ContactYue He

The Ninth People's Hospital Affiliated to Medical College of Shanghai Jiaotong University

heyuejiuyuan@163.com+86 21-23271699

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026